Posted by Michael Wonder on 09 Feb 2023
Quebec becomes first province to cover Brukinsa (zanubrutinib) for the treatment of Waldenström's macroglobulinemia
6 February 2023 - First and only Bruton's tyrosine kinase inhibitor to be granted provincial formulary approval.
BeiGene Canada announced today that the Government of Quebec will publicly fund Brukinsa (zanubrutinib), a second generation inhibitor of Bruton's tyrosine kinase, for the treatment of adult patients with Waldenström's macroglobulinaemia, a rare blood cancer.
As of 1 February 2023, Brukinsa will be included on the list of medications reimbursed under the Régie de l'assurance maladie du Québec (RAMQ).
